• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于多发病家族性非髓样甲状腺癌的患病率

On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds.

作者信息

Charkes N David

机构信息

Section of Nuclear Medicine, Temple University Hospital, Philadelphia, Pennsylvania 19140, USA.

出版信息

Thyroid. 2006 Feb;16(2):181-6. doi: 10.1089/thy.2006.16.181.

DOI:10.1089/thy.2006.16.181
PMID:16613533
Abstract

Clinical and genetic studies of familial nonmedullary thyroid cancer (FNMTC) have yielded conflicting results concerning the aggressiveness of the tumors, and uncertainty of their genetic makeup. In most reports of multiply affected families, the composition of the kindreds has favored families of 2 affected members. Using data for differentiated thyroid cancer (DTC) provided by the Surveillance Epidemiology and End Results (SEER) branch of the National Cancer Institute, and fine-needle aspiration data from Mayo Clinic, I found that the likelihood of 2 cases of sporadic DTC (RR) in a 9-member first-degree family was 1.25% of all DTC families, amounting to 39.4% of 306 multi-hit families reported in the literature. To study the remaining affected families I used the Bernouilli trials model of exact probability. The 60.6% of non-RR, multiply affected families are mostly concentrated in kindreds of 2 to 5 affected members. In 2-hit families, 62%-69% of affected members are sporadic (RR) cases. In families having 3 or more affected members, fewer than 6% have 1 or more sporadic (R) cases, and fewer than 0.15% have 2 or more. In families of 3 to 5 affected members, more than 96% of affected members have the familial (F) trait. Approximately 1 of 338 DTC cases carries the F-trait. Since approximately 40% of multiply affected member first-degree kindreds of DTC, and a significant majority of 2-hit families, are composed of clinically evident, sporadic cases only clinical and genetic investigations of FNMTC should center on families of 3 or more affected members.

摘要

家族性非髓样甲状腺癌(FNMTC)的临床和遗传学研究在肿瘤侵袭性及其基因组成的不确定性方面得出了相互矛盾的结果。在大多数多例受累家庭的报告中,家族构成偏向于有两名受累成员的家庭。利用美国国立癌症研究所监测、流行病学和最终结果(SEER)部门提供的分化型甲状腺癌(DTC)数据以及梅奥诊所的细针穿刺数据,我发现一个九口之家出现两例散发性DTC(RR)的可能性占所有DTC家庭的1.25%,占文献报道的306个多发病例家庭的39.4%。为了研究其余受累家庭,我使用了精确概率的伯努利试验模型。60.6%的非RR多例受累家庭主要集中在有2至5名受累成员的家族中。在双发病例家庭中,62% - 69%的受累成员是散发性(RR)病例。在有3名或更多受累成员的家庭中,少于6%的家庭有1例或更多散发性(R)病例,少于0.15%的家庭有2例或更多。在有3至5名受累成员的家庭中,超过96%的受累成员具有家族性(F)特征。大约每338例DTC病例中有1例具有F特征。由于大约40%的DTC多例受累成员一级亲属以及绝大多数双发病例家庭仅由临床明显的散发病例组成,因此FNMTC的临床和遗传学研究应集中在有3名或更多受累成员的家庭。

相似文献

1
On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds.关于多发病家族性非髓样甲状腺癌的患病率
Thyroid. 2006 Feb;16(2):181-6. doi: 10.1089/thy.2006.16.181.
2
Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.家族性非髓样甲状腺癌的临床特征和结局:一项回顾性对照研究。
Thyroid. 2011 Jan;21(1):43-8. doi: 10.1089/thy.2009.0406. Epub 2010 Oct 18.
3
An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.家族性非髓样甲状腺癌的循证医学方法:筛查、临床管理及随访
World J Surg. 2007 May;31(5):924-33. doi: 10.1007/s00268-006-0847-1.
4
Familial nonmedullary thyroid carcinoma.家族性非髓样甲状腺癌
Cancer Control. 2006 Apr;13(2):106-10. doi: 10.1177/107327480601300204.
5
Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma.家族性非髓样甲状腺癌的临床特征和预后。
Endocrinol Diabetes Nutr (Engl Ed). 2022 Apr;69(4):262-270. doi: 10.1016/j.endien.2022.03.003. Epub 2022 Mar 16.
6
Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members.诊断时年龄在确定有两个受影响成员的家族性非髓样甲状腺癌中的作用。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e855-e865. doi: 10.1210/clinem/dgaa798.
7
Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.家族性非髓样甲状腺癌:筛查、临床、分子及遗传学发现
Biochim Biophys Acta. 2014 Dec;1846(2):468-76. doi: 10.1016/j.bbcan.2014.09.002. Epub 2014 Sep 11.
8
The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.FOXE1 基因座是家族性非髓样甲状腺癌的一个主要遗传决定因素。
Int J Cancer. 2014 May 1;134(9):2098-107. doi: 10.1002/ijc.28543. Epub 2013 Oct 31.
9
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.遗传性非髓样甲状腺癌的临床特征和遗传易感性。
Thyroid. 2009 Dec;19(12):1343-9. doi: 10.1089/thy.2009.1607.
10
Familial nonmedullary thyroid cancer.家族性非髓样甲状腺癌
Thyroid. 2005 Jun;15(6):588-93. doi: 10.1089/thy.2005.15.588.

引用本文的文献

1
Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients.家族性非髓样甲状腺癌与散发性分化型甲状腺癌患者无进展生存期的比较
Thyroid. 2025 Jun;35(6):642-651. doi: 10.1089/thy.2024.0588. Epub 2025 May 20.
2
Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.非综合征性家族性甲状腺癌中突变基因的染色体定位
Front Oncol. 2024 Mar 20;14:1286426. doi: 10.3389/fonc.2024.1286426. eCollection 2024.
3
Identification of a Novel Germline Missense Mutation Asp409Asn on Familial Non-Medullary Thyroid Carcinoma.
家族性非髓样甲状腺癌中新发种系错义突变Asp409Asn的鉴定
Biomedicines. 2024 Jan 22;12(1):244. doi: 10.3390/biomedicines12010244.
4
Family history of malignant or benign thyroid tumors: implications for surgical procedure management and disease-free survival.甲状腺良恶性肿瘤家族史:对手术处理和无病生存的影响。
Front Endocrinol (Lausanne). 2023 Nov 29;14:1282088. doi: 10.3389/fendo.2023.1282088. eCollection 2023.
5
Clinical relevance and outcome of familial papillary thyroid cancer: a single institution study of 626 familial cases.家族性甲状腺乳头状癌的临床意义和结局:一家机构 626 例家族性病例的研究。
Front Endocrinol (Lausanne). 2023 Sep 14;14:1200855. doi: 10.3389/fendo.2023.1200855. eCollection 2023.
6
Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.新型易感性基因驱动大型近亲家族性非髓样甲状腺癌。
Int J Mol Sci. 2023 May 4;24(9):8233. doi: 10.3390/ijms24098233.
7
Indeterminate Thyroid Nodules: When to Worry?甲状腺结节性质不明:何时该担忧?
J Adv Pract Oncol. 2023 Jan;14(1):88-92. doi: 10.6004/jadpro.2023.14.1.9. Epub 2023 Feb 1.
8
The Future of Thyroid Nodule Risk Stratification.甲状腺结节风险分层的未来。
Endocrinol Metab Clin North Am. 2022 Jun;51(2):305-321. doi: 10.1016/j.ecl.2021.12.002. Epub 2022 May 4.
9
Clinical, Laboratory, and Ultrasound Related Diagnoses of Thyroid Disorders: Using a Family Medicine Center Data to Assess Thyroiditis and Thyroid Nodules in the Eastern Province of Saudi Arabia.临床、实验室和超声相关诊断甲状腺疾病:使用家庭医学中心数据评估沙特阿拉伯东部省份的甲状腺炎和甲状腺结节。
J Prim Care Community Health. 2022 Jan-Dec;13:21501319221095345. doi: 10.1177/21501319221095345.
10
Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.与非综合征性家族性非髓样甲状腺癌相关的易感性基因和染色体区域:一些发病机制和诊断关键。
Front Endocrinol (Lausanne). 2022 Feb 28;13:829103. doi: 10.3389/fendo.2022.829103. eCollection 2022.